ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
6.00
-0.02 (-0.33%)
Jun 29, 2026, 1:29 PM EDT - Market open
ImageneBio Revenue
In the year 2025, ImageneBio had annual revenue of $800.00K, down -77.14%.
Revenue (ttm)
$800.00K
Revenue Growth
-77.14%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
67.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 800.00K | -2.70M | -77.14% |
| Dec 31, 2024 | 3.50M | -5.66M | -61.79% |
| Dec 31, 2023 | 9.16M | -6.46M | -41.35% |
| Dec 31, 2022 | 15.62M | -15.37M | -49.59% |
| Dec 31, 2021 | 30.99M | 21.79M | 237.01% |
| Dec 31, 2020 | 9.19M | -4.56M | -33.15% |
| Dec 31, 2019 | 13.75M | 12.76M | 1,289.19% |
| Dec 31, 2018 | 990.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TScan Therapeutics | 9.14M |
| BeyondSpring | 1.88M |
| Seres Therapeutics | 1.15M |
| MediciNova | 596.64K |
| eXoZymes | -700.00 |
IMA News
- 18 days ago - Independent Medical Alliance Launches IMA Academy, Expanding Access to Expert-Led, CME-Accredited Medical Education - Business Wire
- 4 weeks ago - ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York - GlobeNewsWire
- 7 weeks ago - ImageneBio price target lowered to $24 from $30 at Leerink - TheFly
- 7 weeks ago - ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update - GlobeNewsWire
- 7 weeks ago - ImageneBio Quarterly report: Q1 2026 - Filings
- 7 weeks ago - ImageneBio Earnings release: Q1 2026 - Filings
- 2 months ago - ImageneBio Proxy statement: Proxy filing - Filings
- 2 months ago - ImageneBio Proxy statement: Proxy filing - Filings